7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
27 citations
,
August 2024 in “Frontiers in Pharmacology” Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
75 citations
,
June 2005 in “Archives of Dermatology” Etanercept may not prevent alopecia areata from coming back.
July 2023 in “Anais Brasileiros de Dermatologia” Mesalazine showed limited effectiveness in treating children with severe alopecia areata.
June 2022 in “C&EN global enterprise” The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
1 citations
,
October 2015 in “The American journal of gastroenterology” Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.
June 2025 in “British Journal of Dermatology” Denosumab may cause alopecia areata.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
April 2023 in “Journal of Investigative Dermatology” Narrowband Ultraviolet B treatment can significantly reduce anxiety in psoriasis patients, but it doesn't significantly affect depression.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
September 2024 in “Indian Journal of Dermatology Venereology and Leprology” Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
May 2026 in “SHILAP Revista de lepidopterología” Dupilumab effectively treated severe alopecia areata in a child.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
April 2023 in “Journal of Investigative Dermatology” PX-12 may help treat psoriasis by blocking inflammation and cell death.
April 2019 in “Journal of Investigative Dermatology” Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.
January 2018 in “SOJ microbiology & infectious diseases” Etanercept, a psoriasis treatment, caused hair loss in a patient.
20 citations
,
March 2017 in “Arthritis research & therapy” Social media can help compare the effectiveness and safety of new arthritis medications.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.